Antiangiogenic (metronomic) chemotherapy for brain tumors: Current and future perspectives

Expert Opinion on Investigational Drugs

Volumn 18, Issue 7, 2009, Pages 973-983

  Samuel, David P ^a   Wen, Patrick Y ^b   Kieran, Mark W ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adult; Antiangiogenic; Brain tumor; Chemotherapy; Glioblastoma multiforme; Low dose; Metronomic; Pediatric

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUINDOSTATIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IMATINIB; LENALIDOMIDE; MERCAPTOPURINE; MONOCLONAL ANTIBODY DC101; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; RETINOIC ACID; SEMAXANIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CLINICAL TRIAL; ENDOTHELIUM CELL; GLIOMA; HUMAN; LOW DRUG DOSE; NEOVASCULARIZATION (PATHOLOGY); ORTHOTOPIC GLIOMA; OVARY CANCER; REVIEW; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS;

EID: 67650422499     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903025752     Document Type: Review

References (119)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
2. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-8
3. Herrington B, Kieran MW. Small molecule inhibitors in children with malignant gliomas. Pediatr Blood Cancer 2009. In press
4. Wen PY. New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther 2009;9:7-10
5. Kieran MW, Supko JG, D. Wallace D, et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 2009;52:169-76
6. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-60
7. Sarmiento R, Gasparini G. Antiangiogenic metronomic chemotherapy. Onkologie 2008;31:161-2
8. Khosravi Shahi P, Fernandez Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008;26:104-8
9. Newton HB. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Curr Opin Investig Drugs 2007;8:1009-21
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
11. Ergun S, Hohn HP, Kilic N, et al. Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 2008;4:169-77
12. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202
13. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005;65:2507-10
14. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003;220:545-54
15. Laquente B, Vinals F, Germa JR. Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 2007;9:93-8
16. Emmenegger U, Kerbel RS. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie 2007;30:606-8
17. Stempak D, Seely D, Baruchel S. Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest 2006;24:432-43
18. Kieran MW. Anti-angiogenic therapy in pediatric neuro-oncology. J Neurooncol 2005;75:327-34
19. Kieran MW. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat Res 2004;117:337-49
20. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86
21. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24
22. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7
23. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006;42:2335-42
24. Gunther M, Wagner E, Ogris M. Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? J Cell Mol Med 2008;12(6B):2704-16
25. Albertsson P, Lennernas B, Norrby K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncol 2008;47:293-300
26. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-55
27. Ooyama A, Oka T, Zhao HY, et al. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.Cancer Lett 2008;267:26-36
28. Laquente B, Lacasa C, Ginesta MM, et al. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 2008;7:638-47
29. Klink T, Bela C, Stoelting S, et al. Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J Cancer Res Clin Oncol 2006;132:643-52
30. Drevs J, Fakler J, Eisele S, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;24:1759-63
31. Kim JT, Kim JS, Ko KW, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 2006;16:33-9
32. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-32
33. Cejka D, Preusser M, Woehrer A, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008;7:1377-85
34. Bocci G, Falcone A, Fioravanti A, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008;98:1619-29
35. Ma J, Waxman DJ, Modulation OF, et al. Mol Cancer Ther 2008;7:79-89
36. Blansfield JA, Caragacianu D, Alexander HR III, et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008;14:270-80
37. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005;23:939-52
38. Kamat AA, Kim TJ, Landen CN Jr, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-8
39. Yap R, Veliceasa D, Emmenegger U, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-85
40. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-4
41. Shiraga E, Barichello JM, Ishida T, Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int J Pharm 2008;353:65-73
42. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-91
43. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005;65:7045-51
44. Emmenegger U, Morton GC, Francia G, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006;66:1664-74
45. Hermans IF, Chong TW, Palmowski MJ, et al. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63:8408-13
46. Brandes LJ, Israels LG. Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone. Cancer Treat Rep 1982;66:1413-5
47. Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-5
48. Haim N, Ben-Shahar M, Epelbaum R. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer Chemother Pharmacol 1995;36:352-5
49. Needle MN, Molloy PT, Geyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997;29:28-32
50. Allegrini G, Falcone A, Fioravanti A, et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008;98:1312-9
51. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996;14:1922-7
52. Davidson A, Gowing R, Lowis S, et al. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 1997;33:1816-22
53. Chamberlain MC, Kormanik PA. Chronic oral VP-16 for recurrent medulloblastoma. Pediatr Neurol 1997;17:230-4
54. Chamberlain MC. Recurrent intracranial ependymoma in children: salvage therapy with oral etoposide. Pediatr Neurol 2001;24:117-21
55. Sandri A, Massimino M, Mastrodicasa L, et al. Treatment with oral etoposide for childhood recurrent ependymomas. J Pediatr Hematol Oncol 2005;27:486-90
56. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 1996;27:149-55
57. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 1997;54:554-8
58. Mulne AF, Ducore JM, Elterman RD, et al. Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2000;22:41-4
59. Chamberlain MC. Recurrent brainstem gliomas treated with oral VP-16. J Neurooncol 1993;15:133-9
60. Korones DN, Fisher PG, Cohen KJ, Dubowy RL. No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol 2000;35:80-2
61. Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007;9:354-63
62. Kieran MW, Billett A. Antiangiogenesis therapy. Current and future agents. Hematol Oncol Clin North Am 2001;15:835-51,viii
63. Choi LM, Rood B, Kamani N, et al. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 2008;50:970-5
64. Jurado JM, Sanchez A, Pajares B, et al. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008;10:583-6
65. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82
66. Garcia-Saenz JA, Martin M, Calles A, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 2008;20:632-9
67. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-905
68. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225
69. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006;17:961-7
70. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24:3623-8
71. Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 2008;49:447-50
72. Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008;112:2228-32
73. Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177:2136-40; discussion 2140
74. Lin PC, Chen WS, Chao TC, et al. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/ uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol 2007;60:351-6
75. Correale P, Cerretani D, Remondo C, et al. A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006;16:133-40
76. Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003;98:1643-8
77. Nicolini A, Mancini P, Ferrari P, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004;58:447-50
78. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003;52:377-82
79. Young SD, Whissell M, Noble JC, et al. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006;12:3092-8
80. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol 2008;21:736-44
81. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36
82. Sanborn SL, Cooney MM, Dowlati A, et al. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs 2008;26:355-62
83. Chau CH, Wang W, Figg WD. Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis. Cancer Biol Ther 2008;7:1386-7
84. Mccarty MF, Barroso-Aranda J, Contreras F. PPAR gamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation. Med Hypotheses 2008;70:419-23
85. Damato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5
86. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci 1999;889:84-6
87. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-81
88. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 2006;29:308-13
89. Andre N, Rome A, Coze C, et al. Metronomic etoposide/cyclophosphamide/ celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin Ther 2008;30:1336-40
90. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720-8
91. Sterba J, Pavelka Z, Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002;49:117-20
92. Lopez-Aguilar E, Sepulveda-Vildosola AC, Betanzos-Cabrera Y, et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine- fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 2008;39:655-62
93. Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 2008;10:300-8
94. Perry JR, Mason WP, Belanger K, et al. Canadian study of continuous TMZ (50mg/m2) in MG patients progressing on standard TMZ. Am Soc Clin Oncol 2008
95. Perry JR, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the 'rescue' approach. Cancer 2008;113:2152-7
96. Kong DS, Rizek P, Cashman R, et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 2006;16:1117-21
97. Herrlinger U, Rieger J, Steinbach JP, et al. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 2005;71:295-9
98. Bocci G, Tuccori M, Emmenegger U, et al. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol 2005;16:1243-52
99. Tonini G, Schiavon G, Silletta M, et al. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol 2007;3:183-90
100. Suvannasankha A, Fausel C, Juliar BE, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007;12:99-106
101. Bar J, Onn A. Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opin Pharmacother 2008;9:701-15
102. Zhou Q, Guo P, Wang X, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 2007;321:265-75
103. Tas F, Duranyildiz D, Soydinc HO, et al. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol 2008;61:721-5
104. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9
105. Buckstein R, Kerbel RS, Shaked Y et al. High-dose celecoxib and metronomic 'low-dose' cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-8
106. Stoelting S, Trefzer T, Kisro J, et al. Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 2008;22:831-6
107. Loven D, Be'ery E, Yerushalmi R, et al. Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. Acta Oncol 2008;47:104-9
108. Gorn M, Habermann CR, Anige M, et al. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 2008;31:185-9
109. Twardowski PW, Smith-Powell L, Carroll M, et al. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest 2008;26:53-9
110. Lam T, Hetherington JW, Greenman J, Maraveyas A. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 2006;17:113-21
111. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61
112. Emmenegger U, Shaked Y, Man S, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther 2007;6:2280-9
113. Munoz R, Shaked Y, Bertolini F, et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005;14:466-79
114. Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-22
115. Steinbild S, Arends J, Medinger M, et al. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients - results of a phase II study. Onkologie 2007;30:629-35
116. Sandri MT, Johansson HA, Zorzino L, et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 2007;110:509-17
117. Caballero M, Grau JJ, Blanch JL, et al. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2007;133:1143-8
118. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006;17:232-8
119. Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biol Ther 2004;3:1212-3